#HVO hVIVO PLC – Notice of Results April 7, 2026 – Posted in: hVIVO (HVO)

London, UK – 7 April 2026, hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that it will release its final results for the year ended 31 December 2025 on Wednesday 15 April 2026. Analyst briefing A briefing open to equity research analysts will take place on Wednesday 15 April 2026 at 11.00am BST. To register and for more details please contact hVIVO@icrhealthcare.com. Investor presentation Yamin ‘Mo’ Khan,…

#HVO hVIVO PLC – Issue of Equity and Total Voting Rights February 23, 2026 – Posted in: hVIVO (HVO)

London, UK – 23 February 2026, hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces the issue of 1,386,991 new Ordinary Shares of £0.001 each in the Company (“First Consideration Shares”) to three managers of Cryo-Store Limited (“Cryostore”). This issuance comprises the first tranche (50%) of the equity consideration payable pursuant to the acquisition of Cryostore announced on 27 February 2025 (the “Acquisition”). …

#HVO hVIVO PLC – Trading Update January 29, 2026 – Posted in: Uncategorized

London, UK – 29 January 2026, hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, provides a trading update for the year ended 31 December 2025 (FY25). The FY25 financials in this statement remain subject to audit. Highlights • Revenue is expected to be c.£46.7 million (2024: £62.7 million), in line with expectations • Adjusted EBITDA margin is expected to be positive low single-digit* (2024:…

#HVO hVIVO PLC – Notice of Trading Update January 27, 2026 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that it will issue a trading update for the year ended 31 December 2025 on Thursday 29 January 2026. Investor presentation Yamin ‘Mo’ Khan, Chief Executive Officer, and Stephen Pinkerton, Chief Financial Officer, will provide a live presentation relating to the trading update via the Investor Meet Company platform on Thursday 29 January 2026 at 6pm. The…

#HVO hVIVO PLC – Interim results September 23, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces its unaudited interim results for the six months ended 30 June 2025 (“H1 2025”). Financial summary • Revenue of £24.2 million (H1 2024: £35.6 million), in line with expectations of £47 million for the full year · Includes £5.2 million and £0.3 million revenue contribution from CRS and Cryostore respectively • EBITDA (pre-exceptionals*) of…

#HVO hVIVO PLC – Notice of Results September 4, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that it will release its interim results for the six months ended 30 June 2025 on Tuesday 23 September 2025. Analyst briefing A briefing open to equity research analysts will take place on Tuesday 23 September 2025 at 10.30am BST. To register and for more details please contact Walbrook PR on hvivo@walbrookpr.com. Investor presentation Yamin ‘Mo’…

#HVO hVIVO – H1 TRADING UPDATE July 22, 2025 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, provides an unaudited trading update for the six months ended 30 June 2025 (H1 2025). Highlights · Revenue of £24.2 million (H1 2024: £35.6 million), in line with expectations of £47 million for the full year · EBITDA margin (pre-exceptionals) of c.12% (H1 2024: 24.5%) · Cash of £23.3 million as at 30 June 2025 (30 June…

#HVO hVIVO PLC – Directorate Change July 18, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that the Company has received notice of resignation from Tracey James as Non-Executive Director of the Board with immediate effect. The Company can confirm that Ms James’ decision to resign from the Board is unrelated to the Company’s financial performance or outlook. The Company’s trading update for H1 2025 will be issued on 22 July…

#HVO hVIVO PLC – Notice of Trading Update July 9, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that it will issue a trading update for the six months ended 30 June 2025 on Tuesday 22 July 2025. Investor presentation Yamin ‘Mo’ Khan, Chief Executive Officer, and Stephen Pinkerton, Chief Financial Officer, will provide a live presentation relating to the trading update via the Investor Meet Company platform on Tuesday 22 July 2025…

#HVO hVIVO PLC – Director/PDMR Shareholding June 2, 2025 – Posted in: Blog, hVIVO (HVO)

CEO & CFO Share Purchase hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on Friday 30 May 2025, Yamin ‘Mo’ Khan, Chief Executive Officer and Stephen Pinkerton, Chief Financial Officer, purchased shares in the Company as detailed below: Director No of shares purchased Purchase Price Resultant holding Resultant holding as a % of the issued share capital Yamin ‘Mo’ Khan 1,100,000 8.9 pence 5,001,603 0.73% Stephen…